Evidence map›Paper›PMID 36456810›Full record

ArticleBone marrow transplantation2023

Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection.

Xueyan Sun, Haixia Fu, Chencong Wang, Yuanyuan Zhang, Wei Han, Huan Chen, Yu Wang, Qi Chen, Yun He, Qiusha Huang and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 1 country.

Xueyan Sun *Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Haixia Fu *Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Chencong WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yuanyuan ZhangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Wei HanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Huan ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yu WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Qi ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yun HePeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Qiusha HuangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Chenhua YanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yao ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Tingting HanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Meng LvPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaodong MoPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Jingzhi WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Fengrong WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yuhong ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaolu ZhuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Lanping XuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Kaiyan LiuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China. zhangxh@bjmu.edu.cn.ORCID 0000-0003-4730-256X
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clearance of hepatitis B surface antigen (HBsAg) is an ideal therapeutic goal for patients with chronic hepatitis B virus (HBV) infection. Haematopoietic stem cell transplantation (HSCT) is the most effective therapy for a variety of haematological diseases. For patients with chronic HBV infection who received allo-HSCT, recipient hepatitis B serological status might change after allo-HSCT; however, data on the loss of HBsAg following allo-HSCT are relatively rare. We first reviewed patients with chronic HBV infection who received allo-HSCT in our centre from 2010 to 2020, and 125 patients were included in our study. A total of 62 patients (49.6%) with chronic HBV infection achieved HBsAg loss after allo-HSCT. Positivity for HBeAb and HBsAb in donors as well as no cytomegalovirus (CMV) infection were identified as independent risk factors for HBsAg loss after allo-HSCT. A predictive model including positivity for HBeAb and HBsAb in donors and no CMV infection was subsequently developed and performed well with effective discrimination and calibration. In addition, patients could benefit when this model is used in the clinic, as revealed via decision-curve analysis (DCA). However, multicentre prospective studies are required for validation.

Indexed as

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationHepatitis BHepatitis B, ChronicHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B virusHumansHepatitis B AntibodiesHepatitis B Surface Antigens

Identifiers

PMID36456810
OpenAlexW4310603351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.